Mylan launches generic Brevibloc injection in single-dose bags
The Food and Drug Administration has given the green light to Mylan for a generic version of Baxter’s Brevibloc (esmolol hydrochloride in sodium chloride injection, 2,500 mg/250 mL (10 mg/mL) single-dose plastic bag and 2,000 mg/100 mL (20 mg/mL) single-dose plastic bag).
Esmolol hydrochloride in sodium chloride injection is indicated for the short-term treatment of the control of ventricular rates in supraventricular tachycardia, including atrial fibrillation and atrial flutter and control of heart rate in noncompensatory sinus tachycardia and control of perioperative tachycardia and hypertension.
The product had a market value of approximately $126 million for the 12 months ending June 30, 2018, according to IQVIA.
Esmolol hydrochloride in sodium chloride injection is indicated for the short-term treatment of the control of ventricular rates in supraventricular tachycardia, including atrial fibrillation and atrial flutter and control of heart rate in noncompensatory sinus tachycardia and control of perioperative tachycardia and hypertension.
The product had a market value of approximately $126 million for the 12 months ending June 30, 2018, according to IQVIA.